Mehmet Sitki Copur, MD | Authors

September 21, 2020

ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.

August 11, 2020

ABSTRACT Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Several risk stratification classification systems have been developed based on tumor size, mitotic rate, location, and perforation. Traditional chemotherapy and radiation therapy have been very ineffective, making surgery the mainstay of treatment. The discovery of mutations associated with these tumors has revolutionized the treatment approach. Imatinib mesylate, a selective tyrosine kinase receptor inhibitor, used as adjuvant or neoadjuvant therapy, has greatly improved the morbidity and mortality associated with GISTs. As the survival of patients has increased with the long-term use of targeted therapies, quality-of-life issues now have become much more relevant and have come to the forefront of care. We present a young woman who was successfully treated for GIST but now faces associated long-term adverse effects of imatinib, including the challenge of preserving fertility and the potential for childbearing.

July 15, 2020

The coronavirus disease 2019 (COVID-19) pandemic has permanently changed many aspects of clinical care, including clinical trials. A short list of the challenges faced by the entire research community during this pandemic include (but aren’t limited to) enrollment and protocol adherence difficulties, needing to reduce patient visits, staffing constraints, and limited availability of ancillary services.

July 15, 2020

A recap of some of the most notable ASCO 2020 research results in the field of gastrointestinal cancer that may guide oncologists in their day-to-day work.

August 14, 2019

A 51-year-old man noticed abdominal swelling and distention with intermittent abdominal pain, early satiety, and decreased appetite over the past several months. A computed tomography scan of the abdomen is performed. What's your diagnosis?

July 16, 2019

The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31–June 4 in Chicago, drew more than 32,000 oncology specialists from around the world.

July 15, 2019

The US Food and Drug Administration recently approved a new indication for olaparib for maintenance treatment in adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer.

June 14, 2019

May 14, 2019

This article reviews the current state of cancer research around the world.

April 15, 2019

This article reviews patient requests and how they may be in contrast with guidelines, and provides recommendations from a community oncology practice perspective.